Market Report Source

Overview

Alzheimer’s Disease is the most common cause of dementia, constituting 60% to 70% of all cases, and the risk with the disease doubles every 5 years after age 65. Incidence of the disease is increasing, and the resulting attention given to Alzheimer’s Disease has encouraged development of new treatments. There is an opportunity for pharmaceutical companies to compete in this market, as Kalorama analyst Melissa Elder outlines in this study.

This report includes incidence of Alzheimer’s disease worldwide with information for specific geographical regions; world demographics; life expectancy by country, and other general issues affecting the market.

Information is presented as a worldwide overview, with special emphasis on the U.S., Japan, Germany, and other key markets.

A market summary includes market analysis by products on the market and in development, in addition to a a regional market analysis, including:

• US
• Europe
• Japan
• Rest of World

as well as a competitive analysis of leading providers. Additionally key company profiles are included, with profiles of the following companies competing in this therapeutic area:

• Eisai Co., Ltd.
• Forest Laboratories
• H. Lundbeck A/S
• Johnson & Johnson
• Merz Pharma GmbH
• Novartis AG
• Pfizer, Inc.

Markets are broken out by drug type:

• Cholinesterase inhibitors
• NMDA antagonists

as well as by product.

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information.

For the purpose of this study, Kalorama Information conducted interviews with more than 50 key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Additional interviews were completed with relevant company representatives including marketing directors, division managers, and product representatives.

All market data pertains to the world market at the manufacturers’ level. The base year for data was 2007. Historical data was provided for the years 2005 and 2006, with forecast data provided for 2008 through 2012. Compound annual growth rates (CAGRs) are provided for the 2005-2007 and 2008-2012 periods for each region and/or segment covered. Competitive analysis is provided for the year 2007.

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY
Background
Scope and Methodology
Size and Growth of the Market
Key Issues and Trends Affecting Market
Leading Competitors

CHAPTER TWO: INTRODUCTION
Overview
Structural Organization of the Neurological System
Central Nervous System
The Brain
Aging and Alzheimer’s Disease
Stages of Alzheimer’s Disease
Risk Factors
Life Expectancy and the Growing Incidence of Alzheimer’s Disease
World Demographics
Prevalence, Incidence and Mortality
Insurance for the Elderly in the United States
Generic Competition
Teva/Mutual Pharmaceutical/United Research Laboratories and Eisai
Dr. Reddy’s and Novartis
Ranbaxy and Ortho-McNeil Neurologics

CHAPTER THREE: ALZHEIMER’S DISEASE PRODUCT ANALYSIS
Overview of Products
Aricept
Namenda/Exiba/Axura
Exelon
Razadyne
Other Products

CHAPTER FOUR: RESEARCH AND DEVELOPMENT
Overview
Phase III
AAB-001
Aricept SR
Exelon Transdermal Patch (ONO 2540)
Flurizan
LY450139
Memryte
Namenda Once-Daily
Rosiglitazone XR
Xaliproden
Phase II
Dimebon
AC-1202
Ispronicline
MEM-3454
MEM-1003
AN-1792
ABT-089
ACC-001 and QS-21
AL-108
CX717
ELND-005
Huperzine A
Immune globulin, intravenous
LY2062430
Lecozotan SR
MK-0249
MK-0952
Neramenxane
NIC5-15
PRX-03140
Rasagiline mesylate
SAM-531
SGS742
T 817 MA
TTP 488
Phase I
933776
Aricept Transdermal Patch
AV 965
AVE 8112
Bapineuzumab
CAD-106
CERE-110
CTS-21166
EVP 6124
GSI 953
Lecozotan SR
MEM-1414
NGX267
Oxigon
Paz-417
PF-4360365
PF-30804014
R1450
R4996/MEM 63908
SSR 180711
V 950
Preclinical Development
TTP 4000
AAB-002
Alzhemed
BACE Inhibitors (TTP 854)
CX1739
E2012
Gamma-secretase inhibitor
GSI-136
MEM-1917
MPI-442690
PBT2/PBT3/PBT4
SAR 110894

CHAPTER FIVE: MARKET AND COMPETITOR ANALYSIS
Market Overview
Market Analysis by Product Type
Market Analysis by Country
Competitive Analysis
Leading Products

CHAPTER SIX: LEADING MANUFACTURERS
Overview
Eisai Co., Ltd.
Forest Laboratories
H. Lundbeck A/S
Johnson & Johnson
Merz Pharma GmbH
Novartis AG
Pfizer, Inc.

APPENDIX: LIST OF MAJOR COMPANIES LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY
Figure 1-1: Alzheimer’s Disease Market Analysis: 2005-2012

CHAPTER TWO: INTRODUCTION
Table 2-1: Alzheimer’s Disease Stages 1-7 and Descriptions
Table 2-2: Average Life Expectancy in Years by Country 1980, 2004 and 2006
Figure 2-1: Average Life Expectancy in Years by Country 1980, 2004 and 2006
Table 2-3: World Population by Selected Geographical Region, 2007 – 2050
Figure 2-2: World Population by Selected Geographical Region, 2007-2050
Table 2-4: Estimated World Population by Age and Geographical Region, 2007
Figure 2-3: Estimated World Population by Age and Geographical Region, 2007
Table 2-5: Percent Population Over 65 by Year and Region
Figure 2-4: Estimated World Population by Age, 2007 and 2050
Table 2-6: Estimated Prevalence, Incidence and Mortality for Alzheimer’s Disease* by Region/Country, 2007
Figure 2-5: Estimated World Prevalence and Incidence of Alzheimer’s Diseases by Region, 2007
Figure 2-6: World Prevalence of Alzheimer’s Disease Compared to Rest of Population Over Age 65, 2007
Table 2-7: Health Insurance Trends in the United States, Estimated 2007 (millions)

CHAPTER THREE: ALZHEIMER’S DISEASE PRODUCT ANALYSIS

Table 3-1: Comparison of Marketed Alzheimer’s Disease Treatments
Figure 3-1: Alzheimer Product Sales Analysis, 2005-2007
Figure 3-2: Aricept Sales Analysis, 2005-2007
Figure 3-3: Namenda/Exiba/Axura Sales Analysis, 2005-2007
Figure 3-4: Exelon Sales Analysis, 2005-2007
Figure 3-5: Razadyne Sales Analysis, 2005-2007

CHAPTER FOUR: RESEARCH AND DEVELOPMENT
Figure 4-1: Alzheimer’s Disease Treatments in Development, 2005, 2006, and 2007
Table 4-1: Alzheimer’s Disease Therapies in Development

CHAPTER FIVE: MARKET AND COMPETITOR ANALYSIS
Table 5-1: Alzheimer’s Disease Market Analysis, 2005-2007
Table 5-2: Forecasted Alzheimer’s Disease Market Analysis: 2008-2012
Figure 5-1: Alzheimer’s Disease Market Analysis: 2005-2012
Table 5-3: Alzheimer’s Disease Market Analysis by Drug Type, (Cholinesterase inhibitors, NMDA antagonists), 2005-2007
Figure 5-2: Alzheimer’s Disease Market Analysis by Drug Type, (Cholinesterase inhibitors, NMDA antagonists), 2005-2007
Figure 5-3: Alzheimer’s Disease Market Share by Drug Type, (Cholinesterase inhibitors, NMDA antagonists), 2005 Figure 5-4: Alzheimer’s Disease Market Share by Drug Type, (Cholinesterase inhibitors, NMDA antagonists), 2007
Table 5-4: Alzheimer’s Disease Market Analysis by Region/Country, 2007
Figure 5-5: Alzheimer’s Disease Market Analysis by Region/Country, 2007
Table 5-5: Alzheimer’s Disease Market Estimated Revenues and Market Share of Leading Suppliers 2007
Figure 5-6: Alzheimer’s Disease Market Estimated Market Share by Leading Suppliers 2007
Table 5-6: Alzheimer’s Disease Market Estimated Sales of Top Products 2007
Figure 5-7 : Alzheimer’s Disease Market Estimated Market Share of Top Products, 2007

CHAPTER SIX: LEADING MANUFACTURERS
Figure 6-1: Eisai’s Net Revenues and R&D Expenses for 2006 and 2007
Figure 6-2: Forest’s Net Revenues and R&D Expenses for 2006 and 2007
Figure 6-3: Lundbeck’s Net Revenues and R&D Expenses for 2006 and 2007
Figure 6-4: Johnson & Johnson’s Net Revenues and R&D Expenses for 2006 and 2007
Figure 6-5: Merz Pharma’s Net Revenues and R&D Expenses for 2006 and 2007
Figure 6-6: Novartis’ Net Revenues and R&D Expenses for 2006 and 2007
Figure 6-7: Pfizer’s Net Revenues and R&D Expenses for 2006 and 2007